Your session is about to expire
← Back to Search
Genetic Testing
Reporting of Adult-Onset Genomic Results in Pediatric Patients
Phase < 1
Waitlist Available
Led By Adam H Buchanan, MS, MPH, CGC
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Any pediatric MyCode participant (ages 0-17)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 6, &12 months post-disclosure
Awards & highlights
Summary
This trial will assess the psychological effects on children and their parents who receive genomic results, as well as health behaviors of parents whose children receive an adult- or pediatric-onset genomic result.
Who is the study for?
This trial is for children (ages 0-17) enrolled in the MyCode study and their parents. It's not open to those who've already had genetic counseling for conditions like colorectal cancer, high cholesterol, or breast and ovarian cancer syndrome through other studies or routine care.Check my eligibility
What is being tested?
The study looks at how getting genomic results about diseases that could affect them as adults impacts kids and their families. Some will get info on adult-onset conditions, others on pediatric-onset ones, while a control group won't receive any results.See study design
What are the potential side effects?
There are no direct medical side effects since this isn't a drug trial. However, receiving genetic information may cause psychological distress or impact family dynamics and health behaviors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am under 18 and part of the MyCode study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1, 6, &12 months post-disclosure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 6, &12 months post-disclosure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Health-Related Quality of Life (HRQOL)
Initiation of risk reduction behavior
The General Functioning 12-item subscale (GF12) of The McMaster Family Assessment Device (FAD)
+2 moreSecondary outcome measures
Body Image instrument
Children's Revised Impact of Events scale
Decision Regret scale
+4 moreTrial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Receive an adult-onset resultExperimental Treatment1 Intervention
Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with adult onset of disease.
Group II: Receive a pediatric-onset resultExperimental Treatment1 Intervention
Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with pediatric onset of disease or with risk reduction interventions that begin in childhood.
Group III: Control - No resultActive Control1 Intervention
Compare change in psychosocial outcomes and health behaviors of those without a genomic result.
Find a Location
Who is running the clinical trial?
National Human Genome Research Institute (NHGRI)NIH
263 Previous Clinical Trials
283,722 Total Patients Enrolled
Geisinger ClinicLead Sponsor
149 Previous Clinical Trials
1,883,066 Total Patients Enrolled
Adam H Buchanan, MS, MPH, CGCPrincipal InvestigatorGeisinger - Genomic Medicine Institute
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have received genetic counseling for a condition that can be treated.You have already received genetic counseling for the specific conditions being studied in another research study.I am under 18 and part of the MyCode study.
Research Study Groups:
This trial has the following groups:- Group 1: Receive an adult-onset result
- Group 2: Receive a pediatric-onset result
- Group 3: Control - No result
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger